ClinicalTrials.gg
RecruitingNCT07713797Updated Aug 3, 2026

Biomarkers for Endometriosis

An observational study in Endometriosis, sponsored by Trio Fertility. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Trio Fertility · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Endometriosis with a site in Canada — 12 open to participants now, 13 under way, none of them phase 3. Endometriosis · Canada.

Planned enrollment
7th of 11
100 · median 126
Started
2026
with 1 other
Observational
11 of 34
5 open now
Primary completion
2027-01
later than 3 of 12 live
Registered
32nd of 34
by date

Among the 34 studies in Endometriosis with a site in Canada, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2026, is one of 11 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 32nd registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

12 of the 34 studies in Endometriosis with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Endometriosis with a site in Canada, or all of them as a file.
02

Study summary

Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, often causing pain and infertility. Currently, endometriosis can only be definitively diagnosed through invasive procedures like laparoscopy and biopsy.

The purpose of this study is to investigate whether the proteins Synuclein Gamma (SNCG) and B-Cell Lymphoma 6 (BCL6), measurable in blood and menstrual fluid, can serve as non-invasive biomarkers to diagnose or monitor endometriosis.

Read the detailed description

Background:

Endometriosis is a benign inflammatory disease defined by the presence of endometrial glands and stroma in areas outside the uterus[1]. It is estimated to affect 5%-15% of women of reproductive age [2] and is even more prevalent among women with chronic pelvic pain and infertility [3]. Endometriotic implants may be located anywhere within the pelvis, including the ovaries, pelvic peritoneum, rectovaginal septum, uterosacral ligaments, and cul-de sac. The pathophysiology of endometriosis still remains unclear. The etiologic mechanism most widely accepted is retrograde menstruation resulting in tubal backflow of endometrial cells into the pelvis during menses [4]. Over time, these cells may adhere to peritoneal surfaces, proliferate, and progressively grow. The amount, duration, and frequency of pelvic exposure to menstrual bleeding may also determine the severity of endometriosis [5]. At present, the diagnosis of endometriosis can only be definitively made by laparoscopy and biopsy of endometrial lesions for histologic confirmation. Since these are invasive procedures and usually performed at the late stages, there is an urgent need to identify non-invasive biomarkers to effectively indicate endometriosis especially at the early stages for better clinical management.

Rational:

Many genes and proteins have been proposed as biomarkers for diagnosis and follow up of endometriosis [6, 7], but none used at the present time is sensitive and specific enough either to diagnose endometriosis nor to determine the effectiveness of treatment of endometriosis. Synuclein gamma (SNCG), a member of the synuclein family of neuronal proteins, is involved in cellular proliferation by interacting with the mitotic checkpoint kinase BubR1, and inhibiting its regulatory role on cellular proliferation [8]. During the last decade, several studies have demonstrated that SNCG is correlated with poor outcome of breast cancer, ovarian cancer, colon cancer and pancreatic cancer. Interestingly, SNCG has previously been shown to have elevated expression ranging from 5- to 53-fold in ovarian endothelial cells of endometriosis lesions compared with eutopic endometrium from the same individual [9]. Similarly, B-Cell Lymphoma 6 (BCL6) protein is encoded by the BCL6 oncogene and is a zinc finger transcription factor that regulates the transcription of signal transducer and activators of transcription (STAT)-dependent IL-4 responses of B-cells [10]. Previously, BCL6 was shown to express in the endometrial epithelial cells and B-cells in lymph node germinal centres [11,12]. In addition, over-expression of BCL6 has been reported in endometrial biopsies and has been linked to the progesterone resistance and pathogenesis of endometriosis [13]. Together, both of these proteins (SNCG and BCL6) have been linked to endometriosis. However, their diagnostic/prognostic utility by non-invasive means such as measurement in peripheral blood and menstrual fluid of patients with endometriosis remains to be investigated.

Hypothesis:

The research team hypothesize that SNCG and BCL6 concentrations are altered in patients with endometriosis and measurements of circulating SNCG and BCL6 levels in serum/menstrual blood could be used for diagnosis and/or prognosis of endometriosis.

OBJECTIVES

Objectives:

The aim of this study is to measure the SNCG and BCL6 concentrations in peripheral and menstrual fluid from endometriosis patients compared to age-matched healthy subjects or in patients after the treatment of endometriosis. The research team have the following specific objectives:

  1. Identification of endometriosis and control groups and sample collection: Eligible patients with active endometriosis (n=100) confirmed through standard clinical diagnosis will be recruited along with age matched healthy control subjects (n=50). Peripheral blood and menstrual fluid samples will be collected from both of these groups. In addition, the endometriosis group will be followed post treatment (either medically or surgically) and their blood and menstrual fluids samples will be collected at the 3rd and 6th month safter treatment. These collected samples will be processed for serum/supernatant isolation and stored at -80 C until further analysis.
  2. Analysis of circulatory SNCG and BCL6 levels using ELISA method: SNCG and BCL6 levels in serum/menstrual supernatant will be quantitated using specific ELISA kits and will be compared for significant differences in patients with endometriosis from control subjects as well as their changes before and after the treatment in endometriosis group.

Expected Outcome and significance:

The research team expect that SNCG and BCL6 concentrations in patients with endometriosis would be significantly higher compared to age-matched healthy subjects. In addition, the investigators expect that SNCG and BCL6 concentrations may also show differences in samples of endometriosis patients treated with suppression medication or after surgery. This study aims to validate their diagnostic/prognostic potential of SNCG and BCL6 concentrations as non-invasive biomarkers for endometriosis.

STUDY DESIGN This study will focus on measuring circulatory SNCG and BCL6 concentrations in patients with endometriosis compared to age-matched healthy subjects without endometriosis. Patients with confirmed endometriosis, and the healthy control group will be recruited at TRIO Fertility following informed consent. Peripheral blood samples and menstrual samples will be collected from both groups and serum/supernatant from these samples will be used for measuring the baseline differences of SNCG and BCL6 levels. In addition, post-treatment changes in these proteins will also be measured in samples collected from endometriosis patients at the 3rd and 6th month following endometriosis suppression with dienogest, Lupron depot and addback, or Myfembree, or after laparoscopic surgery with excision or vaporization of endometriosis lesions. Analysis of circulatory SNCG/BCL6 levels will be performed using SNCG and BCL6 specific enzyme linked immunosorbent assays (ELISA), respectively, and will be compared for significant differences between the endometriosis and the control group, and pre and post treatment in endometriosis group.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • endometriosis
  • biomarkers
  • BCL6
  • SNCG
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

This study will focus on measuring circulatory SNCG and BCL6 concentrations in patients with endometriosis compared to age-matched healthy subjects without endometriosis. Patients with confirmed endometriosis, and the healthy control group will be recruited at TRIO Fertility following informed consent.

Eligibility criteria

Inclusion Criteria for Endometriosis Group:

  • Women of reproductive age group (18Y-45Y).
  • Women with active endometriosis diagnosed by ultrasound/MRI/laparoscopy.

Exclusion Criteria for Endometriosis Group:

  • Women \<18Y and >45Y.
  • Women with endometriosis during stimulation with gonadotropins.
  • Current or prior history of uterine, ovarian, colon, pancreatic, breast or any other type of cancer.
  • Any prior history of chronic illness.
  • Pregnant women.

Inclusion Criteria for Control Group:

  • Women of reproductive age group (18Y-45Y).
  • Women without endometriosis and any other gynaecological problem.

Exclusion Criteria for Endometriosis Group:

  • Women \<18Y and >45Y
  • Prior history of any disease including cancer or chronic illness.
  • Pregnant women.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Endometriosis Group

    Patients who have been diagnosed with Endometriosis

    Diagnostic Test: SNCG Protein · Diagnostic Test: BCL-6 Protein

  • Control Group

    Patients who have not been diagnosed with Endometriosis

    Diagnostic Test: SNCG Protein · Diagnostic Test: BCL-6 Protein

Interventions

  • Diagnostic testSNCG Protein

    Synuclein gamma (SNCG), a member of the synuclein family of neuronal proteins, is involved in cellular proliferation by interacting with the mitotic checkpoint kinase BubR1, and inhibiting its regulatory role on cellular proliferation. During the last decade, several studies have demonstrated that SNCG is correlated with poor outcome of breast cancer, ovarian cancer, colon cancer and pancreatic cancer. Interestingly, SNCG has previously been shown to have elevated expression ranging from 5- to 53-fold in ovarian endothelial cells of endometriosis lesions compared with eutopic endometrium from the same individual.

  • Diagnostic testBCL-6 Protein

    B-Cell Lymphoma 6 (BCL6) protein is encoded by the BCL6 oncogene and is a zinc finger transcription factor that regulates the transcription of signal transducer and activators of transcription (STAT)-dependent IL-4 responses of B-cells. Previously, BCL6 was shown to express in the endometrial epithelial cells and B-cells in lymph node germinal centers. In addition, over-expression of BCL6 has been reported in endometrial biopsies and has been linked to the progesterone resistance and pathogenesis of endometriosis

06

What researchers measure

Primary outcomes

  1. Synuclein Gamma (SNCG) and B-cell Lymphoma 6 (BCL-6) Levels

    Synuclein Gamma (SNCG) and B-cell Lymphoma 6 (BCL-6) levels (ng/ml) in serum/menstrual supernatant will be quantitated using specific ELISA kits and will be compared for significant differences in patients with endometriosis from control subjects as well as their changes before and after the treatment in endometriosis group.

    Time frame: Baseline for control participants and baseline and approximately 3 months after treatment for participants with endometriosis

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — SNCG and BCL-6 levels

Supporting information: Study protocol, Informed consent form

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 11 months is below that.

Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jul 20, 2026
StartActual
Jan 16, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07713797
Lead sponsor
Trio Fertility
Responsible party
Dr. Robert F. Casper (Principal Investigator, Trio Fertility) — Principal investigator
First posted
Jul 20, 2026
Start date
Jan 16, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Yasaman Sadeghi, M.Sc.
Contact
yasamans@triofertility.com
4165060804

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion